Peptide derivatives

• US 5,252,705 A
• Filed: 12/11/1991
• Issued: 10/12/1993
• Est. Priority Date: 04/12/1990
• Status: Expired due to Fees

• Current Assignee: Mitsubishi Kasei Corp. (Mitsubishi Chemical Group Corp.)
• Original Assignee: Mitsubishi Kasei Corp. (Mitsubishi Chemical Group Corp.)
• Inventors: Nakao, Kenichiro, Mori, Akihisa, Kanmera, Tatsuhiko, Nakao, Yoshihide
• Primary Examiner(s): Wityshyn, Michael G.
• Assistant Examiner(s): SAYALA, CHHAYA D
• Application Number:
  US07/778,926
• Time in Patent Office: 671 Days
• Field of Search: 530/324, 514/12, 514/21
• US Class Current: 530/324
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 3/14 for calcium homeostasis vitamin D A61P3/02; parathyroid hormones A61P5/18; calcitonin A61P5/22; osteoporosis A61P19/10; bone metastasis A61P35/04
• CPC Class Codes: C07K 14/635 Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
• CPC Class Codes: Y02P 20/55 Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

The present invention relates to the peptides consisting of 25-50 amino acid residues and comprising the following peptide sequence:

Leu-Met-His-Asn-Leu-Gly-Lys-Ser-Ile-Gln-Asp-Leu-Arg-Arg-Arg-Phe-Phe-Leu-His

-His-Leu-Ile-Ala-Glu-Ile (I)

and amides and salts thereof. The peptides have stronger inhibitory activity against hPTH when compared with conventional inhibitors, and therefore, they are expected to be useful for the treatment of various diseases associated with calcium or phosphoric acid metabolism such as hypercalcemia and osteoporosis, or diseases associated with PTH and PTHrP.

Claims

1. Peptides consisting of 28-32 amino acid residues and comprising the following peptide sequence:

space="preserve" listing-type="equation">X-Leu-Met-His-Asn-Leu-Gly-Lys-Ser-Ile-Gln-Asp-Leu-Arg-Arg-Arg-Phe-Phe-Leu-His-His-Leu-Ile-Ala-Glu-Ile-His-Thr-Ala (I)

wherein X represents H, H-Gln, H-A-Gln-, H-Glu-A-Gln, or Ser-Glu-A-Gln-, wherein A is Ile, Thr, Val, or Leu, and amides and salts thereof.